+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease



The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease



American Heart Journal 146(6): 1007-1014



Cholesteryl ester transfer protein (CETP) regulates plasma lipid distribution. A polymorphism in the CETP gene (Taq1B) is associated with CETP activity, HDL concentration, atherosclerosis progression, and response to statins, and may influence cardiovascular (CV) events. We studied CETP Taq1B genotype, plasma HDL, and clinical events among all patients and patients stratified by statin treatment. Consenting patients (n = 2531) with significant coronary artery disease (> or =1 lesion of > or =70% stenosis) undergoing coronary arteriography were genotyped, grouped by statin prescription at hospital discharge, and prospectively followed-up for the outcomes of all-cause mortality and myocardial infarction. CETP Taq1B genotype frequencies were: B1B1, 32.9%; B1B2, 50.3%; and B2B2 16.8%. Plasma HDL was reduced for B1B1 patients (33 +/- 12 mg/dL, vs 36 +/- 13 mg/dL and 36 +/- 13 mg/dL for B1B2 and B2B2, respectively, P for trend =.003). Overall, event rates did not differ between genotypes. Event rates were similar among untreated (24.8%) and statin-treated (24.2%) B1 homozygotes (P = NS); statins significantly reduced events for B1B2 subjects (28.0% vs 21.0%, P =.009) and for B2B2 subjects (26.4% vs 17.4%, P =.048). Therapeutic benefit for B2 carriers remained after adjustment for covariates, and regression interaction analysis showed that B2 carriers experienced reduced events (relative risk [RR] 0.62, 95% CI 0.45-0.86), but statins did not benefit those with B1B1 (RR 1.09, 95% CI 0.70-1.7; P for interaction =.02). Findings were similar for the end point of death alone, although a modest benefit was seen in B1B1 patients (RR 0.67, P =.10), in addition to the strong benefit for B1B2 (RR 0.53, P =.001) and B2B2 (RR 0.28, P =.001). The CETP Taq1B polymorphism is associated with differential HDL levels but no significant differential in CV risk in the absence of treatment. Importantly, however, CV event reduction by statin therapy is substantially enhanced in the presence of a B2 allele. Our findings suggest, for the first time, the potential of CETP Taq1B genotyping to enable more effective, pharmacogenetically directed therapy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012638831

Download citation: RISBibTeXText

PMID: 14660992

DOI: 10.1016/s0002-8703(03)00501-5


Related references

Statin therapy and the cholesterol ester transfer protein Taq1B polymorphism Lack of survival benefit for B1B1 genotype among patients with angiographically-defined coronary artery disease. Circulation 104(17 Supplement): II 449, October 23, 2001

Cholesteryl ester transfer protein Taq1B polymorphism in an angiographically assessed Turkish population: no effects on coronary artery disease risk. Genetic Testing and Molecular Biomarkers 14(5): 637-642, 2011

Effects of cholesterol ester transfer protein Taq1B gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients. Cell Biochemistry and Function 23(1): 23-28, 2004

Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. Journal of the American College of Cardiology 41(11): 1983-1989, June 4, 2003

The I405V but not Taq1B polymorphism in the cholesteryl ester transfer protein gene is associated with LDL particle size. Journal of the American College of Cardiology 37(2 Supplement A): 296A, 2001

Taq1B polymorphism of cholesteryl ester transfer protein (CETP) gene in primary combined hyperlipidaemia. Indian Journal of Medical Research 129(3): 293-298, 2009

Effects of cholesteryl ester transfer protein TAQ1B polymorphism in renal transplant patients. Transplantation Proceedings 38(5): 1382-1384, 2006

Cholesteryl ester transfer protein gene polymorphism (I405V) and premature coronary artery disease in an Iranian population. Bosnian Journal of Basic Medical Sciences 16(2): 114-120, 2017

Cholesteryl Ester Transfer Protein Taq1B (g.5454G>A) Gene Polymorphism in Primary Combined Hyperlipidemia in the Egyptian Population. Laboratory Medicine 42(8): 482-486, 2011

Taq1B polymorphism of cholesteryl ester transfer protein (CETP) in Egyptian patients with metabolic syndrome. Diabetes and Metabolic Syndrome 5(2): 61-65, 2013

Cholesteryl ester transfer protein rs1532624 gene polymorphism is associated with reduced response to statin therapy. Current Molecular Pharmacology 6(3): 156-162, 2015

Association between cholesteryl ester transfer protein Taq1B polymorphism with lipid levels in primary hyperlipidemic patients. European Journal of Lipid Science and Technology 110(3): 225-231, 2008

Newly detected gene variation of the cholesteryl ester transfer protein strongly predicts prognosis and response to statin therapy. European Heart Journal 23(Abstract Supplement): 197, August-September, 2002

Taq1B Polymorphism of Cholesteryl Ester Transfer Protein (CETP) and Its Effects on the Serum Lipid Levels in Metabolic Syndrome Patients. Biochemical Genetics 54(6): 894-902, 2016

Association of the Taq1 cholesteryl ester transfer protein gene polymorphism with high-density lipoprotein cholesterol and coronary artery disease in Asian populations. American Journal of Human Genetics 69(4 Supplement): 387, 2001